首页> 外文期刊>Bone marrow transplantation >Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant
【24h】

Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant

机译:患有兄弟供体与脐带血液移植相比,慢性移植物与宿主病的结果

获取原文
获取原文并翻译 | 示例
           

摘要

We compared chronic graft-versus-host disease (cGvHD) following umbilical cord blood (UCBT) and matched sibling donor peripheral blood transplant (MSD). 145 patients (2010-2017) with cGvHD after MSD (n = 104) and UCBT (n = 41) were included. Prior acute GvHD was less frequent in MSD (55% vs. 85%; p = 0.01). Severe cGvHD (32% vs. 15%, p = 0.01) and de-novo onset (45% vs. 15%, p = 90 at cGvHD diagnosis was associated with higher odds of response (95%CI: 1.42-10, p < 0.01). The cumulative incidence of durable discontinuation of immune-suppressive therapy, failure-free survival (FFS) and NRM at 2-years were similar between cohorts. KPS < 90 (95%CI: 3.1-24.9, p < 0.01) and platelets <100 x 10e9/L (95%CI: 1.25-10, p = 0.01) were associated with higher risk of NRM. UCBT patients were more likely to have a prior acute GvHD, less severe cGvHD and more likely to attain CR. Despite differences, both cohorts had similar NRM and FFS. High-risk groups, including those with platelets <100 x 10e9/L and KPS < 90, need careful monitoring and intensified therapy.
机译:在脐带血(UCBT)之后比较慢性接枝与宿主疾病(CGVHD)和匹配的兄弟供体外周血移植(MSD)。在MSD(n = 104)和UCBT(n = 41)之后,145例患者(2010-2017)用CGVHD(n = 41)。在MSD中的急性GVHD较少(55%对85%; P = 0.01)。严重的CGVHD(32%vs.15%,P = 0.01)和De-Novo发作(45%对15%,CGVHD诊断的P = 90与较高的反应几率有关(95%CI:1.42-10,P <0.01)。核心抑制治疗的耐用停止,失败的存活(FF)和NRM之间的累积发生率在群组中相似。KPS <90(95%CI:3.1-24.9,P <0.01)血小板<100×10E9 / L(95%CI:1.25-10,p = 0.01)与NRM的风险较高有关。UCBT患者更容易发生出现的急性GVHD,不太严重的CGVHD,更可能获得CR 。尽管存在差异,但两个群组都有类似的NRM和FFS。高风险群体,包括血小板<100 x 10E9 / L和KPS <90的那些,需要仔细监测和强化治疗。

著录项

  • 来源
    《Bone marrow transplantation》 |2021年第6期|共8页
  • 作者单位

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Dept Pediat Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Dept Pediat Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Dept Pediat Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Biostat Clin Translat Sci Inst CTSI Minneapolis MN USA;

    H Lee Moffitt Canc Ctr &

    Res Inst Dept Blood &

    Marrow Transplant &

    Cellular Immunot Tampa FL USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Dept Pediat Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

    Univ Minnesota Div Hematol Oncol &

    Transplantat Minneapolis MN 55455 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号